...
首页> 外文期刊>Virology Journal >Transmitted drug resistance and transmission clusters among HIV-1 treatment-na?ve patients in Guangdong, China: a cross-sectional study
【24h】

Transmitted drug resistance and transmission clusters among HIV-1 treatment-na?ve patients in Guangdong, China: a cross-sectional study

机译:中国广东省HIV-1治疗-NA'VE患者透射耐药性和透射簇:横断面研究

获取原文

摘要

Transmitted drug resistance (TDR) that affects the effectiveness of the first-line antiretroviral therapy (ART) regimen is becoming prevalent worldwide. However, its prevalence and transmission among HIV-1 treatment-na?ve patients in Guangdong, China are rarely reported. We aimed to comprehensively analyze the prevalence of TDR and the transmission clusters of HIV-1 infected persons before ART in Guangdong. The HIV-1 treatment-na?ve patients were recruited between January 2018 and December 2018. The HIV-1 pol region was amplified by reverse transcriptional PCR and sequenced by sanger sequencing. Genotypes, surveillance drug resistance mutations (SDRMs) and TDR were analyzed. Genetic transmission clusters among patients were identified by pairwise Tamura-Nei 93 genetic distance, with a threshold of 0.015. A total of 2368 (97.17%) HIV-1 pol sequences were successfully amplified and sequenced from the enrolled 2437 patients. CRF07_BC (35.90%, 850/2368), CRF01_AE (35.56%, 842/2368) and CRF55_01B (10.30%, 244/2368) were the main HIV-1 genotypes circulating in Guangdong. Twenty-one SDRMs were identified among fifty-two drug-resistant sequences. The overall prevalence of TDR was 2.20% (52/2368). Among the 2368 patients who underwent sequencing, 8 (0.34%) had TDR to protease inhibitors (PIs), 22 (0.93%) to nucleoside reverse transcriptase inhibitors (NRTIs), and 23 (0.97%) to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Two (0.08%) sequences showed dual-class resistance to both NRTIs and NNRTIs, and no sequences showed triple-class resistance. A total of 1066 (45.02%) sequences were segregated into 194 clusters, ranging from 2 to 414 sequences. In total, 15 (28.85%) of patients with TDR were included in 9 clusters; one cluster contained two TDR sequences with the K103N mutation was observed. There is high HIV-1 genetic heterogeneity among patients in Guangdong. Although the overall prevalence of TDR is low, it is still necessary to remain vigilant regarding some important SDRMs.
机译:透过影响第一线抗逆转录病毒治疗(ART)方案的有效性的透射耐药性(TDR)正在全球变得普遍。然而,中国广东省艾滋病毒治疗-NA患者的患病率和传播很少报道。我们旨在在广东艺术前全面分析艾滋病毒1受感染者的TDR和传输簇的患病率。 HIV-1治疗-NA'VE患者于2018年1月至2018年12月之间招募。通过逆转录PCR扩增HIV-1 POL区域并通过Sanger测序测序。基因型,分析监测耐药性突变(SDRMS)和TDR。患者中的遗传传输簇通过成对的Tamura-Nei 93遗传距离来鉴定,阈值为0.015。总共2368(97.17%)HIV-1 POL序列被成功扩增并从注册的2437名患者中测序。 CRF07_BC(35.90%,850/2368),CRF01_AE(35.56%,842/2368)和CRF55_01B(10.30%,244/2368)是广东循环的主要HIV-1基因型。在五十二次耐药序列中鉴定了二十一只SDRMS。 TDR的总体流行率为2.20%(52/2368)。在接受测序的2368名患者中,8(0.34%)与蛋白酶抑制剂(PIS),22(0.93%)的核苷逆转录酶抑制剂(NRTIS)和23(0.97%)与非核苷逆转录酶抑制剂( nnrtis)。两种(0.08%)序列显示出对NRTIS和NNRTIS的双级抗性,并且没有显示序列的三级抗性。将1066(45.02%)序列分离成194个簇,范围为2至414个序列。总共包括15名(28.85%)的TDR患者包含在9个集群中;一组含有两个TDR序列,观察到K103N突变。广东患者中有高HIV-1遗传异质性。虽然TDR的总体流行率低,但仍然有必要对一些重要的SDRMS保持警惕。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号